Volker Auwärter

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 54

Top Topics

Liquid Chromatography

Mass Spectrometry

Emergency Department

Top Venues

Drug testing and analysis

Archives of toxicology

Clinical toxicology (Philadelphia, Pa.)

European journal of mass spectrometry (Chichester, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Omayema Taoussi, Diletta Berardinelli, Simona Zaami, Francesco Tavoletta, Giuseppe Basile, Robert Kronstrand, Volker Auwärter, Francesco Paolo Busardò, Francesco P Busardò
Human metabolism of four synthetic benzimidazole opioids: isotonitazene, metonitazene, etodesnitazene, and metodesnitazene. Archives of toxicology 98 (7) (2024)
Omayema Taoussi, Diletta Berardinelli, Simona Zaami, Francesco Tavoletta, Giuseppe Basile, Robert Kronstrand, Volker Auwärter, Francesco Paolo Busardò, Francesco P Busardò
Human metabolism of four synthetic benzimidazole opioids: isotonitazene, metonitazene, etodesnitazene, and metodesnitazene. Archives of toxicology 98 (7) (2024)
Arianna Giorgetti, Annette Zschiesche, Olwen Groth, Belal Haschimi, Martin Scheu, Guido Pelletti, Paolo Fais, Frank Musshoff, Volker Auwärter
ADB-HEXINACA-a novel synthetic cannabinoid with a hexyl substituent: phase I metabolism in authentic urine samples, a case report and prevalence on the German market. Drug testing and analysis (2024)
Omayema Taoussi, Diletta Berardinelli, Simona Zaami, Francesco Tavoletta, Giuseppe Basile, Robert Kronstrand, Volker Auwärter, Francesco Paolo Busardò, Francesco P Busardò
Human metabolism of four synthetic benzimidazole opioids: isotonitazene, metonitazene, etodesnitazene, and metodesnitazene. Archives of toxicology 98 (7) (2024)
Annette Zschiesche, Martin Scheu, Detlef Thieme, Annekathrin Martina Keiler, Benedikt Pulver, Laura M Huppertz, Volker Auwärter
Insights into the metabolism of CH-PIATA-A novel synthetic cannabinoid featuring an acetamide linker. Journal of analytical toxicology 48 (5) (2024)
Liesl K Janssens, Michaela J Sommer, Katharina Elisabeth Grafinger, Maren Hermanns-Clausen, Volker Auwärter, Christophe Pol Stove
Interpreting mono- and poly-SCRA intoxications from an activity-based point of view: JWH-018 equivalents in serum as a comparative measure. Archives of toxicology (2024)
Omayema Taoussi, Diletta Berardinelli, Simona Zaami, Francesco Tavoletta, Giuseppe Basile, Robert Kronstrand, Volker Auwärter, Francesco Paolo Busardò, Francesco P Busardò
Human metabolism of four synthetic benzimidazole opioids: isotonitazene, metonitazene, etodesnitazene, and metodesnitazene. Archives of toxicology (2024)
Arianna Giorgetti, Pietro Brunetti, Belal Haschimi, Benedikt Pulver, Jennifer Paola Pascali, Jan Riedel, Volker Auwärter
Human phase-I metabolism of three synthetic cannabinoids bearing a cumyl moiety and a cyclobutyl methyl or norbornyl methyl tail: Cumyl-CBMEGACLONE, Cumyl-NBMEGACLONE, and Cumyl-NBMINACA. Drug testing and analysis (2024)
Johannes Kutzler, Aldo Eliano Polettini, Sergej Bleicher, Christoph Sauer, Wolfgang Schultis, Merja A Neukamm, Volker Auwärter
Synthetic cannabinoids in hair-Prevalence of use in abstinence control programs for driver's license regranting in Germany. Drug testing and analysis (2023)
Willi Schirmer, Volker Auwärter, Julia Kaudewitz, Stefan Schürch, Wolfgang Weinmann
Identification of human hexahydrocannabinol metabolites in urine. European journal of mass spectrometry (Chichester, England) (2023)
Verena Angerer, Yasmin Schmid, Florian Franz, Heike Gnann, Jan Manuel Speer, Anke Gnann, Stephan Helmecke, Armin Buchwald, Simon D Brandt, Torsten Passie, Matthias E Liechti, Volker Auwärter
Acute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study. Drug testing and analysis (2023)
Ascanio Sirignano, Diletta Berardinelli, Arianna Giorgetti, Hannes Max Schwelm, Belal Haschimi, Susi Pelotti, Francesco Paolo Busardò, Volker Auwärter
Human metabolism and basic pharmacokinetic evaluation of AP-238: A recently emerged acylpiperazine opioid. Drug testing and analysis (2023)
Simon D Brandt, Pierce V Kavanagh, Folker Westphal, Benedikt Pulver, Hannes Max Schwelm, Alexander Stratford, Volker Auwärter, Adam L Halberstadt
Analytical and behavioral characterization of N-ethyl-N-isopropyllysergamide (EIPLA), an isomer of N 6 -ethylnorlysergic acid N,N-diethylamide (ETH-LAD). Drug testing and analysis (2023)
Hannes Max Schwelm, Mattias Persson, Benedikt Pulver, Max Vincent Huß, Henrik Green, Volker Auwärter
Pharmacological profile, phase I metabolism, and excretion time profile of the new synthetic cathinone 3,4-Pr-PipVP. Drug testing and analysis (2023)
Arianna Giorgetti, Ascanio Sirignano, Susi Pelotti, Volker Auwärter
Detection of AP-237 and synthetic cannabinoids on an infused letter sent to a German prisoner. Drug testing and analysis 14 (10) (2022)
Michaela J Sommer, Sebastian Halter, Verena Angerer, Volker Auwärter, Florian Eyer, Gesine Liebetrau, Martin Ebbecke, Maren Hermanns-Clausen
Effect of new legislation in Germany on prevalence and harm of synthetic cannabinoids. Clinical toxicology (Philadelphia, Pa.) 60 (10) (2022)
Benedikt Pulver, Torsten Schönberger, Diana Weigel, Matthias Köck, Yvonne Eschenlohr, Tobias Lucas, Nika Podlesnik, Jason Sirleaf, Wolfgang Dreiseitel, Michael Pütz, Jan Schäper, Andrea Jacobsen-Bauer, Volker Auwärter, Folker Westphal
Structure elucidation of the novel synthetic cannabinoid Cumyl-Tosyl-Indazole-3-Carboxamide (Cumyl-TsINACA) found in illicit products in Germany. Drug testing and analysis 14 (8) (2022)
Benedikt Pulver, Svenja Fischmann, Folker Westphal, Torsten Schönberger, Jan Schäper, Dennis Budach, Andrea Jacobsen-Bauer, Wolfgang Dreiseitel, Johannes Zagermann, Angela Damm, Siegfried Knecht, Jason Sirleaf, Volker Auwärter, Michael Pütz
The ADEBAR project: European and international provision of analytical data from structure elucidation and analytical characterization of NPS. Drug testing and analysis 14 (8) (2022)
Lorina Otte, Maurice Wilde, Volker Auwärter, Katharina Elisabeth Grafinger
Investigation of the μ- and κ-opioid receptor activation by eight new synthetic opioids using the [ 35 S]-GTPγS assay: U-47700, isopropyl U-47700, U-49900, U-47931E, N-methyl U-47931E, U-51754, U-48520, and U-48800. Drug testing and analysis 14 (7) (2022)
Arianna Giorgetti, Ascanio Sirignano, Belal Haschimi, Francesco Paolo Busardò, Susi Pelotti, Volker Auwärter
Human phase-I metabolism and prevalence of two synthetic cannabinoids bearing an ethyl ester moiety: 5F-EDMB-PICA and EDMB-PINACA. Drug testing and analysis (2022)
Benedikt Pulver, Jan Riedel, Torsten Schönberger, Sebastian Halter, Tobias Lucas, Jason Sirleaf, Katharina Elisabeth Grafinger, Martin Scheu, Annette Zschiesche, Michael Pütz, Klaus Pützer, Folker Westphal, Volker Auwärter
Pharmacology, prevalence in Germany, and analytical data of cyclobutylmethyl- and norbornylmethyl-type synthetic cannabinoid receptor agonists. Drug testing and analysis (2022)
Benedikt Pulver, Jan Riedel, Folker Westphal, Steven Luhn, Torsten Schönberger, Jan Schäper, Volker Auwärter, Anton Luf, Michael Pütz
A new synthetic cathinone: 3,4-EtPV or 3,4-Pr-PipVP? An unsuccessful attempt to circumvent the German legislation on new psychoactive substances. Drug testing and analysis (2022)
Simon D Brandt, Pierce V Kavanagh, Folker Westphal, Benedikt Pulver, Hannes Max Schwelm, Kyla Whitelock, Alexander Stratford, Volker Auwärter, Adam L Halberstadt
Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD. Drug testing and analysis 14 (8) (2022)
Benedikt Pulver, Jan Riedel, Torsten Schönberger, Sebastian Halter, Tobias Lucas, Jason Sirleaf, Katharina Elisabeth Grafinger, Martin Scheu, Annette Zschiesche, Michael Pütz, Klaus Pützer, Folker Westphal, Volker Auwärter
Pharmacology, prevalence in Germany, and analytical data of cyclobutylmethyl- and norbornylmethyl-type synthetic cannabinoid receptor agonists. Drug testing and analysis (2022)
Pierce V Kavanagh, Folker Westphal, Benedikt Pulver, Hannes Max Schwelm, Alexander Stratford, Volker Auwärter, Stephen J Chapman, Adam L Halberstadt, Simon D Brandt
Analytical profile of the lysergamide 1cP-AL-LAD and detection of impurities. Drug testing and analysis (2022)
Katharina Elisabeth Grafinger, Marthe M Vandeputte, Annelies Cannaert, Adam Ametovski, Eric Sparkes, Elizabeth Cairns, Patrick Osamu Juchli, Belal Haschimi, Benedikt Pulver, Samuel D Banister, Christophe Pol Stove, Volker Auwärter
Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays. Drug testing and analysis 13 (7) (2021)
Belal Haschimi, Katharina Elisabeth Grafinger, Benedikt Pulver, Evangelia Psychou, Sebastian Halter, Laura M Huppertz, Folker Westphal, Michael Pütz, Volker Auwärter
New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl-CBMICA and Cumyl-CBMINACA. Drug testing and analysis 13 (8) (2021)
Katharina Elisabeth Grafinger, Annelies Cannaert, Adam Ametovski, Eric Sparkes, Elizabeth Cairns, Samuel D Banister, Volker Auwärter, Christophe Pol Stove
Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays-Part II: Structure activity relationship assessment via a β-arrestin recruitment assay. Drug testing and analysis 13 (7) (2021)
Adam Ametovski, Elizabeth A Cairns, Katharina Elisabeth Grafinger, Annelies Cannaert, Marie H Deventer, Shuli Chen, Xinyi Wu, Caitlin E Shepperson, Felcia Lai, Ross Ellison, Roy Gerona, Karen Blakey, Richard C Kevin, Iain S McGregor, David E Hibbs, Michelle Glass, Christophe Pol Stove, Volker Auwärter, Samuel D Banister
NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity? ACS chemical neuroscience 12 (21) (2021)
Arianna Giorgetti, Rossella Barone, Guido Pelletti, Marco Garagnani, Jennifer Pascali, Belal Haschimi, Volker Auwärter
Development and validation of a rapid LC-MS/MS method for the detection of 182 novel psychoactive substances in whole blood. Drug testing and analysis (2021)
Simon D Brandt, Pierce V Kavanagh, Folker Westphal, Alexander Stratford, Peter Blanckaert, Geraldine Dowling, Matthias Grill, Hannes Max Schwelm, Volker Auwärter, Stephen J Chapman
Separating the wheat from the chaff: Observations on the analysis of lysergamides LSD, MIPLA, and LAMPA. Drug testing and analysis (2021)
Caitlyn Norman, Sebastian Halter, Belal Haschimi, Dean Acreman, Josie Smith, Alex J Krotulski, Amanda L A Mohr, Barry K Logan, Niamh Nic Daéid, Volker Auwärter, Craig McKenzie
A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: Comparing prison and general populations. Drug testing and analysis 13 (4) (2021)
Arianna Giorgetti, Michaela J Sommer, Maurice Wilde, Markus Große Perdekamp, Volker Auwärter
A case of fatal multidrug intoxication involving flualprazolam: distribution in body fluids and solid tissues. Forensic toxicology 40 (1) (2021)
Edward Pike, Katharina Elisabeth Grafinger, Annelies Cannaert, Adam Ametovski, Jia Lin Luo, Eric Sparkes, Elizabeth A Cairns, Ross Ellison, Roy Gerona, Christophe Pol Stove, Volker Auwärter, Samuel D Banister
Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays: Part I-Synthesis, analytical characterization, and binding affinity for human CB1 receptors. Drug testing and analysis 13 (7) (2021)
Christina Grumann, Kerstin Henkel, Simon D Brandt, Alexander Stratford, Torsten Passie, Volker Auwärter
Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration. Drug testing and analysis 12 (8) (2020)
Sebastian Halter, Belal Haschimi, Lukas Mogler, Volker Auwärter
Impact of legislation on NPS markets in Germany - The rise and fall of 5F-ADB. Drug testing and analysis 12 (6) (2020)
Hannes Max Schwelm, Christina Grumann, Volker Auwärter, Merja A Neukamm
Application of a chiral high-performance liquid chromatography-tandem mass spectrometry method for the determination of 13 related amphetamine-type stimulants to forensic samples: Interpretative hypotheses. Drug testing and analysis 12 (9) (2020)
Florian Franz, Belal Haschimi, Leslie A King, Volker Auwärter
Extraordinary long detection window of a synthetic cannabinoid metabolite in human urine - Potential impact on therapeutic decisions. Drug testing and analysis 12 (3) (2020)
Sebastian Halter, Benedikt Pulver, Maurice Wilde, Belal Haschimi, Folker Westphal, Jan Riedel, Michael Pütz, Torsten Schönberger, Stefanie Stoll, Jan Schäper, Volker Auwärter
Cumyl-CBMICA: A new synthetic cannabinoid receptor agonist containing a cyclobutyl methyl side chain. Drug testing and analysis 13 (1) (2020)
Christina Grumann, Laura M Huppertz, Philippe Bisel, Verena Angerer, Volker Auwärter
Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3-fluorophenmetrazine (3-FPM). Drug testing and analysis 11 (7) (2019)
Belal Haschimi, Lukas Mogler, Sebastian Halter, Arianna Giorgetti, Bernd Schwarze, Folker Westphal, Svenja Fischmann, Volker Auwärter
Detection of the recently emerged synthetic cannabinoid 4F-MDMB-BINACA in "legal high" products and human urine specimens. Drug testing and analysis 11 (9) (2019)
Bjoern Moosmann, Philippe Bisel, Folker Westphal, Maurice Wilde, Jürgen Kempf, Verena Angerer, Volker Auwärter
Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864). Drug testing and analysis 11 (3) (2019)
Christophe P Stove, Lukas Mogler, Annelies Cannaert, Volker Auwärter, Christophe Pol Stove
Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L-valine or L-tert-leucine. Drug testing and analysis 11 (8) (2019)
Arianna Giorgetti, Lukas Mogler, Belal Haschimi, Sebastian Halter, Florian Franz, Folker Westphal, Svenja Fischmann, Jan Riedel, Michael Pütz, Volker Auwärter
Detection and phase I metabolism of the 7-azaindole-derived synthetic cannabinoid 5F-AB-P7AICA including a preliminary pharmacokinetic evaluation. Drug testing and analysis 12 (1) (2019)
Katharina Koch, Volker Auwärter, Maren Hermanns-Clausen, Maurice Wilde, Merja A Neukamm
Mixed intoxication by the synthetic opioid U-47700 and the benzodiazepine flubromazepam with lethal outcome: Pharmacokinetic data. Drug testing and analysis (2018)
Lukas Mogler, Maurice Wilde, Laura M Huppertz, Georg Weinfurtner, Florian Franz, Volker Auwärter
Phase I metabolism of the recently emerged synthetic cannabinoid CUMYL-PEGACLONE and detection in human urine samples. Drug testing and analysis 10 (5) (2018)
Lukas Mogler, Florian Franz, Maurice Wilde, Laura M Huppertz, Sebastian Halter, Verena Angerer, Bjoern Moosmann, Volker Auwärter
Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples. Drug testing and analysis 10 (9) (2018)
Sebastian Halter, Verena Angerer, Jörg Röhrich, Olwen Groth, Gabriele Roider, Maren Hermanns-Clausen, Volker Auwärter
Cumyl-PEGACLONE: A comparatively safe new synthetic cannabinoid receptor agonist entering the NPS market? Drug testing and analysis 11 (2) (2018)
Christina Grumann, Volker Auwärter
Separation of positional isomers of nine 2-phenethylamine-derived designer drugs by liquid chromatography-tandem mass spectrometry. Drug testing and analysis (2018)
Lukas Mogler, Florian Franz, Daniel Rentsch, Verena Angerer, Georg Weinfurtner, Mitchell Longworth, Samuel D Banister, Michael Kassiou, Bjoern Moosmann, Volker Auwärter
Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples. Drug testing and analysis 10 (1) (2017)
Maren Hermanns-Clausen, Dieter Müller, Josephine Kithinji, Verena Angerer, Florian Franz, Florian Eyer, Hartmud Neurath, Gesine Liebetrau, Volker Auwärter
Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. Clinical toxicology (Philadelphia, Pa.) 56 (6) (2017)
Merja A Neukamm, Arsham Bahrami, Volker Auwärter, Felix M P Mehne, Eva Höss
Evaluation of KIMS immunoassays on a cobas c 501 analyzer for drugs of abuse and ethyl glucuronide testing in urine for forensic abstinence control. Drug testing and analysis 9 (8) (2017)
Laura M Huppertz, Bjoern Moosmann, Volker Auwärter
Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. Drug testing and analysis 10 (1) (2017)
Verena Angerer, Lukas Mogler, Jan-Patrick Steitz, Philippe Bisel, Cornelius Hess, Clara T Schoeder, Christa Elisabeth Müller, Laura M Huppertz, Folker Westphal, Jan Schäper, Volker Auwärter
Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL-PEGACLONE. Drug testing and analysis 10 (3) (2017)